+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Macimorelin"

Ghrelin receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Ghrelin receptor agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020 - Product Thumbnail Image

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 87 Pages
  • Global
From
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 65 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Macimorelin is a drug used to diagnose adult growth hormone deficiency (AGHD). It is a synthetic form of ghrelin, a hormone that stimulates the release of growth hormone from the pituitary gland. Macimorelin is used to diagnose AGHD in adults, as it can help to differentiate between AGHD and other causes of growth hormone deficiency. It is also used to monitor the effectiveness of growth hormone replacement therapy. Macimorelin is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat a variety of endocrine and metabolic disorders, such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, metabolism, and other bodily functions. The companies in the Macimorelin market include Aeterna Zentaris, Inc., Novo Nordisk A/S, and Pfizer, Inc. Show Less Read more